Baxter International SEC filings, summarized
We read every Baxter International 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track BAX in your inbox
Add Baxter International to your watchlist — free, every morning.
Recent filings
Baxter appoints John Rogers as CFO effective October 1
Baxter appointed John Rogers as executive vice president and CFO, reporting to CEO Andrew Hider, effective October 1, 2026. Rogers joins from Smith+Nephew,…
Baxter appoints John Rogers as CFO effective October 1
Baxter appointed John Rogers, formerly CFO of Smith+Nephew, as executive vice president and CFO effective October 1, 2026, reporting to CEO Andrew Hider.…
Baxter Upsizes Debt Tender Offer to $600 Million and Sets Pricing
Baxter increased its cash tender offer cap from $500 million to $600 million and expects to repurchase all accepted tenders of its 2051, 2046 and 2043…
Baxter Amends Credit Agreement, Raises Net Leverage Limits
Baxter International amended its five-year credit agreement with various lenders, with JPMorgan Chase Bank serving as administrative agent. The amendment…
Baxter Launches Tender Offers for Up to $500 Million of Senior Notes
Baxter International launched cash tender offers on August 4, 2026, to repurchase up to $500 million of its 3.132% senior notes due 2051, 3.500% notes due…
Baxter Interim CFO Anita Zielinski to Resign September 15
Anita Zielinski notified Baxter International on July 31, 2026, that she will resign as interim chief financial officer, senior vice president, chief…
Baxter reports 5% second-quarter sales growth and raises 2026 outlook
Baxter reported second-quarter 2026 sales of $2.96 billion, up 5% on both a reported and organic basis, with U.S. GAAP diluted EPS of $0.26 and adjusted…
Baxter raises 2026 outlook after second-quarter sales rise 5%
Baxter reported second-quarter 2026 sales of $2.96 billion for the period ended June 30, up 5% on both a reported and organic basis, with U.S. GAAP diluted…
Baxter filed Exhibit 99.1 — "Stockholder Engagement Presentation (2026)" as Item 9.01 on 2026-03-19.
Baxter filed Exhibit 99.1 — "Stockholder Engagement Presentation (2026)" as Item 9.01 on 2026-03-19. Investors should review the presentation for…
Baxter furnished a presentation (Exhibit 99.1) to certain stockholders on/after Mar 19, 2026 as part of…
Baxter furnished a presentation (Exhibit 99.1) to certain stockholders on/after Mar 19, 2026 as part of its stockholder engagement program. 📢 $BAX #Baxter…
Baxter filed an 8‑K on Mar 16, 2026: furnished Exhibit 99.1 (Press Release dated Mar 16, 2026) and Exhibit…
Baxter filed an 8‑K on Mar 16, 2026: furnished Exhibit 99.1 (Press Release dated Mar 16, 2026) and Exhibit 104 (Inline XBRL cover page). Item 9.01 only…
Baxter ($BAX) — Mar 16, 2026: Mr.
Baxter ($BAX) — Mar 16, 2026: Mr. Grade is transitioning and Ms. Zielinski has been appointed interim CFO, per the company press release. Press release…
Joel Grade ceased as EVP & CFO of Baxter ($BAX) effective Mar 16, 2026 and will serve as a non‑executive…
Joel Grade ceased as EVP & CFO of Baxter ($BAX) effective Mar 16, 2026 and will serve as a non‑executive advisor through Apr 30, 2026. Under a Mar 15…
Baxter ($BAX) filed an 8‑K on Feb 12, 2026 furnishing a press release (Exhibit 99.1) and an Inline XBRL…
Baxter ($BAX) filed an 8‑K on Feb 12, 2026 furnishing a press release (Exhibit 99.1) and an Inline XBRL cover page (Exhibit 104). Press release dated Feb…
Baxter ($BAX) Board declared a quarterly cash dividend of $0.01 per share, effective Feb 11, 2026.
Baxter ($BAX) Board declared a quarterly cash dividend of $0.01 per share, effective Feb 11, 2026. Payable Apr 1, 2026 to stockholders of record on Feb 27,…
Michael R.
Michael R. McDonnell appointed to Baxter’s Board and Audit Committee (appointed Feb 10, effective Feb 13, 2026). Former CFO of Biogen (Aug 2020–Feb 2025)…
Baxter ($BAX) issued an earnings press release for the period ended Dec 31, 2025 on Feb 12, 2026; the…
Baxter ($BAX) issued an earnings press release for the period ended Dec 31, 2025 on Feb 12, 2026; the press release and attachments are furnished as Exhibit…
Final settlement: Baxter completed tender offers on Dec 22, 2025 to buy any/all 2.600% notes due 2026 and…
Final settlement: Baxter completed tender offers on Dec 22, 2025 to buy any/all 2.600% notes due 2026 and a portion of 1.915% notes due 2027 (2027 purchases…